Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naltrexone and Scopolamine in Major Depression
NCT03386448Phase 4Completed
- Sponsor
- The Taub Group
- Start
- Jan 2018
- Primary completion
- Nov 2018
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of naltrexone, scopolamine in major depressive disorder (MDD), sponsored by The Taub Group. Started Jan 2018; status: completed.
02
Drugs
naltrexonescopolamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03386448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03386448.